Zoekresultaten - Prani Paka

  • Toon 1 - 3 resultaten van 3
Verfijn jouw resultaten
  1. 1
    Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The <scp>ALFA</scp> study

    Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The <scp>ALFA</scp> study door Murielle Roussel, Nathalie Texier, Virginie Naël, Jacopo Bitetti, Prani Paka, Naima Kerbouche, L. Saïl, Xavier Colin, Xavier Leleu

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development door Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial

    Gepubliceerd in 2025
    Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study

    Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study door Peter Feng Wang, Christopher Yee, Boris Gorsh, Miriam L. Zichlin, Prani Paka, Rachel H. Bhak, Natalie Boytsov, Anamika Khanal, Ahmed Noman, Maral DerSarkissian, Shannon Ferrante, Mei Sheng Duh

    Gepubliceerd in 2022
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: